These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 3517187)
1. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus. Kim KS; Wass CA; Kang JH; Anthony BF J Infect Dis; 1986 Jun; 153(6):1092-7. PubMed ID: 3517187 [TBL] [Abstract][Full Text] [Related]
2. Relative functional activity of purified human immunoglobulin G against a type III group B streptococcal strain. Kim KS; Kang JH; Concepcion NF; Anthony BF Infect Immun; 1986 Jun; 52(3):908-10. PubMed ID: 3519467 [TBL] [Abstract][Full Text] [Related]
3. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models. Givner LB; Edwards MS; Baker CJ J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837 [TBL] [Abstract][Full Text] [Related]
4. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease. Givner LB; Baker CJ J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763 [TBL] [Abstract][Full Text] [Related]
5. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models. Givner LB Pediatrics; 1990 Dec; 86(6):955-62. PubMed ID: 2123536 [TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin therapy of neonatal group B streptococcal infections: an overview. Fischer GW Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S13-6. PubMed ID: 3041355 [TBL] [Abstract][Full Text] [Related]
7. A human IgG 3 is opsonic in vitro against type III group B streptococci. Kim JS; Kim KS; Wass CA; Short JA; Heiner DC J Clin Immunol; 1990 May; 10(3):154-9. PubMed ID: 2195055 [TBL] [Abstract][Full Text] [Related]
8. Type III group B Streptococcus: functional interaction with IgG subclass antibodies. Givner LB; Baker CJ; Edwards MS J Infect Dis; 1987 Mar; 155(3):532-9. PubMed ID: 3543156 [TBL] [Abstract][Full Text] [Related]
9. Modified human immune serum globulin for intravenous administration: in vitro opsonic activity and in vivo protection against group B streptococcal disease in suckling rats. Fischer GW; Hunter KW; Wilson SR Acta Paediatr Scand; 1982 Jul; 71(4):639-44. PubMed ID: 6753478 [TBL] [Abstract][Full Text] [Related]
10. Polyvalent group B streptococcal immune globulin for intravenous administration: overview. Fischer GW; Hemming VG; Gloser HP; Bachmayer H; von Pilar CE; Wilson SR; Baron PA Rev Infect Dis; 1990; 12 Suppl 4():S483-9; discussion S489-91. PubMed ID: 2194273 [TBL] [Abstract][Full Text] [Related]
11. Potential use of intravenous immune globulin for group B streptococcal infection. Baker CJ; Noya FJ Rev Infect Dis; 1990; 12 Suppl 4():S476-82. PubMed ID: 2194272 [TBL] [Abstract][Full Text] [Related]
12. The opsonic antibody response of female rats to type III group B streptococcal immunization: a model for maternal immunity. Heiman HS; Weisman LE Vet Immunol Immunopathol; 1990 Jan; 24(1):79-89. PubMed ID: 2180204 [TBL] [Abstract][Full Text] [Related]
13. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci. Fischer GW; Wilson SR; Hunter KW J Clin Immunol; 1982 Apr; 2(2 Suppl):31S-35S. PubMed ID: 7045156 [TBL] [Abstract][Full Text] [Related]
14. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648 [TBL] [Abstract][Full Text] [Related]
15. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci. Hill HR; Gonzales LA; Knappe WA; Fischer GW; Kelsey DK; Raff HV J Infect Dis; 1991 Apr; 163(4):792-8. PubMed ID: 2010632 [TBL] [Abstract][Full Text] [Related]
16. Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci. Albanyan EA; Edwards MS Infect Immun; 2000 Oct; 68(10):5794-802. PubMed ID: 10992487 [TBL] [Abstract][Full Text] [Related]
17. Immune globulin for intravenous use: enhancement of in vitro opsonophagocytic activity of neonatal serum. Givner LB; Edwards MS; Anderson DC; Baker CJ J Infect Dis; 1985 Feb; 151(2):217-20. PubMed ID: 3918123 [TBL] [Abstract][Full Text] [Related]
18. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody. Kim KS; Wass CA; Hong JK; Concepcion NF; Anthony BF Pediatr Res; 1988 Nov; 24(5):628-32. PubMed ID: 3060825 [TBL] [Abstract][Full Text] [Related]
19. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus. Choi MJ; Noh JY; Cheong HJ; Kim WJ; Lin SM; Zhi Y; Lim JH; Lim S; Seo HS; Song JY Hum Vaccin Immunother; 2018 Jan; 14(1):67-73. PubMed ID: 28933634 [TBL] [Abstract][Full Text] [Related]